SAN FRANCISCO, Nov. 28 – Millennium Pharmaceuticals on Tuesday announced it had begun Phase I clinical trials for its first molecule directed against a genomically- derived target for metabolic disease.

The compound, called MLN4760, was synthesized by Millennium and was designed with the hope of providing a treatment for obesity. Millennium, based in Cambridge, Mass., partnered with Abbott Park, Ill.-based Abbott Laboratories in the development of the drug.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.